Abstract: Objective To finding lncRNAs associated with ovarian cancer progression and platinum-based chemoresistance， and provide novel detection markers for early screening and treatment options for ovarian cancer. Methods Differentially expressed lncRNAs were screened from cisplatin-resistant ovarian cancer cell lines. The ovarian cancer sequencing data in the TCGA and GTEx databases were analyzed to compare the expression of LINC01151 in ovarian cancer tissues， paracancerous tissues， metastatic tumor tissues， and the overall life cycle of patients. The expression levels of LINC01151 were detected in 25 clinical samples of ovarian cancer tumor tissues and adjacent tissues， and the expression of LINC01151 in normal ovarian epithelial cells and different ovarian cancer cell lines was compared， as well as cisplatin-sensitive ovarian cancer cells and cisplatin-induced ovarian cells. The expression of LINC01151 in cancer cells was analyzed for the association of LINC01151 with tumorigenesis and drug resistance. Results Differentially expressed lncRNAs were screened from cisplatin-resistant ovarian cancer cell lines， and the expression of LINC01151 was significantly different. The relevant data in the chip showed that LINC01151 was highly expressed in cisplatin-resistant ovarian cancer cell lines. It was found by qPCR that LINC01151 was highly expressed in ovarian cancer tissues and cells， and LINC01151 was highly expressed in cisplatin-induced cell lines compared with cisplatin-sensitive cells. Conclusion LINC01151 may be a marker of chemotherapy resistance in ovarian cancer. It is of great significance to reduce the cost of over-treatment and to take timely interventions to avoid the missed optimal cure time and improve the prognosis of cancer patients.

Key words: ovarian cancer, biomarker, cisplatin, chemoresistance, lncRNA

摘要： 目的 寻找和卵巢癌发生、进展以及铂类化疗耐药相关的lncRNA，从而为卵巢癌早期筛查和治疗方案的选择提供新型检测标志物。方法 从顺铂耐药卵巢癌细胞株芯片筛选差异表达的lncRNA，分析TCGA和GTEx数据库中的卵巢癌测序数据，比较LINC01151在卵巢癌组织、癌旁组织、转移肿瘤组织中表达情况，及与患者整体生存周期的相关性。25对卵巢癌肿瘤组织和癌旁组织临床样本中检测LINC01151的表达水平，比较正常卵巢上皮细胞和不同卵巢癌细胞株中LINC01151的表达，以及顺铂敏感卵巢癌细胞和顺铂诱导耐药的卵巢癌细胞中LINC01151的表达，分析LINC01151与肿瘤发生、耐药的相关联。结果 从顺铂耐药卵巢癌细胞株芯片中筛选差异表达的lncRNA，其中LINC01151表达差异显著。芯片中相关数据显示，LINC01151特异性在顺铂耐药的卵巢癌细胞株中高表达。通过qPCR验证发现，LINC01151在卵巢癌组织和细胞中特异性高表达，且与顺铂敏感细胞相比，顺铂诱导耐药的细胞株中LINC01151高表达。结论 LINC01151可能是卵巢癌铂类耐药的标志物，可能可以作为卵巢癌的诊断或预后的生物标志物；临床应用中利用LINC01151对患者进行筛选、分类，有利于精准化、个体化治疗，可能对改善肿瘤患者预后具有重要意义。

关键词: lncRNA, 顺铂, 铂类耐药, 卵巢癌, 生物标志物, LINC01151